How cancer cells rewire their metabolism to survive

January 31, 2013
This shows cells proliferating in an intestinal tumor. Credit: Sanford-Burnham Medical Research Institute

Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfires—glucose-starved tumors actually get more aggressive. In a study published January 31 in the journal Cell, researchers at Sanford-Burnham Medical Research Institute discovered that a protein called PKCζ is responsible for this paradox. The research suggests that glucose depletion therapies might work against tumors as long as the cancer cells are producing PKCζ.

According to this study, when PKCζ is missing from , tumors are able to use alternative nutrients. What's more, the lower the PKCζ levels, the more aggressive the tumor.

"We found an interesting correlation in colon cancers—if a patient's tumor doesn't produce PKCζ, he has a poorer prognosis than a similar patient with the protein. We looked specifically at colon cancer in this study, but it's likely also true for other tumor types," said Jorge Moscat, Ph.D., a professor in Sanford-Burnham's -designated Cancer Center. Moscat led the study in close collaboration with Sanford-Burnham colleague Maria Diaz-Meco, Ph.D.

PKCζ keeps tumors addicted to glucose, and under control

Although most cancer cells love glucose, tumors lacking PKCζ grow even better in the absence of this nutrient. Using human tumor samples and a of , Moscat and his team determined this growth-without-glucose paradox is because PKCζ-deficient tumors are able to reprogram their metabolism to use glutamine, another nutrient, instead.

Without PKCζ around to keep them addicted to glucose, these tumors kick-start a new . This altered metabolism helps PKCζ-deficient cancer cells survive in conditions that would otherwise be lethal.

"If we can find an effective way to add PKCζ back to tumors that lack it, we'd make them less suited for survival and more sensitive to current therapies," Moscat said.

Explore further: Metabolic profiles essential for personalizing cancer therapy

Related Stories

Metabolic profiles essential for personalizing cancer therapy

February 7, 2012
One way to tackle a tumor is to take aim at the metabolic reactions that fuel their growth. But a report in the February Cell Metabolism shows that one metabolism-targeted cancer therapy will not fit all. That means that ...

Protein controlling glucose metabolism also a tumor suppressor

December 6, 2012
A protein known to regulate how cells process glucose also appears to be a tumor suppressor, adding to the potential that therapies directed at cellular metabolism may help suppress tumor growth. In their report in the Dec. ...

How cells sense nutrients and fuel cancer cell growth

October 6, 2011
In cancer, genes turn on and off at the wrong times, proteins aren't folded properly, and cellular growth and proliferation get out of control. Even a cancer cell's metabolism goes haywire, as it loses the ability to appropriately ...

For brain tumors, origins matter

November 13, 2012
(Medical Xpress)—Since stem cells and progenitor cells are regulated by different growth factors, brain tumors arising from these cells might respond differently to different therapies. Researchers at Sanford-Burnham Medical ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.